Chimeric Antigen Receptor (CAR) T-cell Therapy Market Insights Forecast 2027

Global Chimeric Antigen Receptor (CAR) T-cell Therapy Market Research Report: (2022-2027)

By Drug Class (Yescarta (axicabtagene ciloleucel), Kymriah (tisagenlecleucel),Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Others (Abecma (Idecabtagene vicleucel), etc.))... ... e vicleucel), etc.)), By Application (Acute Lymphocytic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Multiple Myeloma, Others (Mantle Cell Lymphoma, etc.)), By End-User (Hospitals, Clinics, Specialty Cancer Centers), By Region (North America, South America, Europe, Middle East & Africa, Asia-Pacific), By Country (The US, Canada, Mexico, Brazil, The UK, Germany, France, Italy, Spain, South Africa, GCC, China, Japan, India, Australia, South East Asia), By Company (Amgen Inc., Bluebird Bio, Inc., Bristol Myers Squibb, CARsgen Therapeutics, Gilead Sciences, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sorrento Therapeutics, Inc., Others) Read more

Healthcare
Jun 2022
Pages 192
Report Format: PDF, Excel, PPT

Market Definition

CAR T-cell therapy is a type of immunotherapy that uses altered immune cells (T-cells) to find & attack tumor cells. During the therapy, a patient’s T cells are extracted & genetically altered to express a CAR (Chimeric Antigen Receptor) that recognizes a protein on the surface of cancer cells. The modified T-cells are then multiplied & infused back into the patient, where they identify & destroy tumor cells and might remain in the body for months after the infusion.

The therapy can result in severe side effects, which is why patients stay in the hospital for a week or two for monitoring. Its efficacy in the treatment of hematologic malignancies has been well-proved, and there are numerous ongoing research activities to identify if it helps treat solid tumors.

Market Insights

The Global Chimeric Antigen Receptor (CAR) T-cell Therapy Market is projected to register exponential CAGR during the forecast period, i.e., 2022-27. The growth of the market would be driven primarily by the burgeoning adoption of CAR T-cell therapy to address the rising patient pool for blood cancers, including lymphomas, certain forms of leukemia, & also multiple myeloma, on account of the mounting awareness regarding its benefits over traditional treatments.

Report Coverage	Details
Study Period	Historical Data: 2017-20
	Base Year: 2021
	Forecast Period: 2022-27
Regions Covered	North America: The US, Canada, Mexico
	Europe: Germany, The UK, Germany, France, Italy, Spain, Rest of Europe
	Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific
	South America: Brazil, Rest of Latin America
	Middle East & Africa: South Africa, GCC, Rest of Middle East & Africa
Key Companies Profiled	Amgen Inc., Bluebird Bio, Inc., Bristol Myers Squibb, CARsgen Therapeutics, Gilead Sciences, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sorrento Therapeutics, Inc., Others
Unit Denominations	USD Million/Billion

Various ongoing R&D activities in the life science & biotechnology sectors across numerous countries for blood cancer treatment using chimeric antigen receptors to evaluate CAR T-cell therapy's effectiveness, safety, mechanism of drug action, and adherence in patients with lymphoma & leukemia are also augmenting the overall growth of the global market.

The approvals of Kymriah & Yescarta earlier in 2017, their expansion across Japan & Europe during 2018-19, and their steadily growing global sales have proved to be a milestone for the Global CAR T-cell Therapy Market. Since then, there have been rapid & notable developments in the field as researchers are tweaking the efficacy & safety of CAR T-cells using novel approaches.

Despite the immense success of CAR T-cell therapy in treating blood cancers, there's still a major missing to its full potential since its application is limited only to certain liquid tumors in relapsed & refractory stages. Challenges like complex manufacturing & supply chain, high costs, and delayed preapproval reimbursement for patients are affecting its commercialization and, in turn, hampering the market growth.

However, with the optimization of autologous CAR T-cells for liquid malignancies, expansion of healthcare facilities, and fast & innovative developments of effective biomarkers to treat solid tumors, the Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market could witness remunerative prospects over the coming years.

Introduction
1. Research Process
2. Assumption
3. Market Segmentation
4. Market Definition
Executive Summary
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Trends & Insights
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Regulation & Policy, By Country
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Dynamics
1. Growth Drivers
2. Challenges
3. Impact Analysis
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Hotspot and Opportunities
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Drug Class
    1. Yescarta (axicabtagene ciloleucel)
    2. Kymriah (tisagenlecleucel)
    3. Tecartus (brexucabtagene autoleucel)
    4. Breyanzi (lisocabtagene maraleucel)
    5. Others (Abecma (Idecabtagene vicleucel), etc.)
  2. By Application
    1. Acute Lymphocytic Leukemia (ALL)
    2. Diffuse Large B-cell Lymphoma (DLBCL)
    3. Follicular Lymphoma
    4. Multiple Myeloma
    5. Others (Mantle Cell Lymphoma, etc.)
  3. By End-User
    1. Hospitals
    2. Clinics
    3. Specialty Cancer Centers
  4. By Region
    1. North America
    2. South America
    3. Europe
    4. Middle East & Africa
    5. Asia-Pacific
  5. By Company
    1. Competition Characteristics
    2. Revenue Shares
    3. Competitor Placement in MarkNtel Advisor’s Quadrant
North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Drug Class
  2. By Application
  3. By End-User
  4. By Country
    1. The US
    2. Canada
    3. Mexico
South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Drug Class
  2. By Application
  3. By End-User
  4. By Country
    1. Brazil
    2. Rest of Latin America
Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Drug Class
  2. By Application
  3. By End-User
  4. By Country
    1. The UK
    2. Germany
    3. France
    4. Italy
    5. Spain
    6. Rest of Europe
Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Drug Class
  2. By Application
  3. By End-User
  4. By Country
    1. South Africa
    2. GCC
    3. Rest of Middle East & Africa
Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Drug Class
  2. By Application
  3. By End-User
  4. By Country
    1. China
    2. Japan
    3. India
    4. Australia
    5. South East Asia
    6. Rest of Asia Pacific
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Key Strategic Imperatives for Success and Growth
Competitive Outlook
1. Competition Matrix
  1. By Application Portfolio
  2. Brand Specialization
  3. Target Markets
  4. Target by Applications
  5. Research & Development
  6. Strategic Alliances
  7. Strategic Initiatives
2. Company Profiles (Business Description, By Application Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
  1. Amgen Inc.
  2. Bluebird Bio, Inc.
  3. Bristol Myers Squibb
  4. CARsgen Therapeutics
  5. Gilead Sciences, Inc.
  6. Merck & Co., Inc.
  7. Novartis International AG
  8. Pfizer Inc.
  9. Sorrento Therapeutics, Inc.
  10. Others
Disclaimer

MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

Full Name*:

Company Name*:

Business Email*:

Country Name*:

Contact Number*:

Message:

Flexible Licensing Options

We offer flexible licensing options to cater to varying organizational needs. Choose the pricing pack that best suits your requirements:

Buy Now

Inquire Before Buying